Fetal malformations and early embryonic gene expression response in cynomolgus monkeys maternally exposed to thalidomide

Reproductive Toxicology

Volumn 29, Issue 1, 2010, Pages 49-56

  Ema, Makoto ^a   Ise, Ryota ^b   Kato, Hirohito ^b   Oneda, Satoru ^c   Hirose, Akihiko ^a   Hirata Koizumi, Mutsuko ^a   Singh, Amar V ^d   Knudsen, Thomas B ^e   Ihara, Toshio ^b  

^a NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

^b SHIN NIPPON BIOMEDICAL LABORATORIES LTD   (Japan)

^c SNBL USA Ltd   (United States)

^d LOCKHEED MARTIN   (United States)

^e U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

Author keywords

Cynomolgus monkey; Embryo; Fetal malformation; Gene expression profile; Teratogenicity; Thalidomide

Indexed keywords

ACTIN; INSULIN; RNA; THALIDOMIDE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRACHYDACTYLY; CONTROLLED STUDY; CYTOSKELETON; DOWN REGULATION; EMBRYO; EMBRYOTOXICITY; ENVIRONMENTAL EXPOSURE; FEMALE; FETUS; FETUS MALFORMATION; GENE CONTROL; GENE EXPRESSION; GESTATION PERIOD; INFLAMMATION; MALE; MICROMELIA; MONKEY; NONHUMAN; PHENOTYPE; PHOCOMELIA; POLYDACTYLY; PRENATAL DRUG EXPOSURE; RNA ISOLATION; SIGNAL TRANSDUCTION; SYNDACTYLY; TERATOGENICITY; UPREGULATION;

ABNORMALITIES, DRUG-INDUCED; ANIMALS; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GESTATIONAL AGE; LIMB DEFORMITIES, CONGENITAL; MACACA FASCICULARIS; MATERNAL-FETAL EXCHANGE; MICROARRAY ANALYSIS; PREGNANCY; RNA; TERATOGENS; THALIDOMIDE;

MACACA FASCICULARIS; PRIMATES;

EID: 73449145248     PISSN: 08906238     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.reprotox.2009.09.003     Document Type: Article

References (39)

1. Schardein J.L., and Macina O.T. Thalidomide. Human developmental toxicants-aspects of toxicology and chemistry (2007), CRC Press, Taylor & Francis Group, Boca Raton p. 127-141
2. Hansen J.M., Carney E.W., and Harris C. Differential alteration by thalidomide of the glutathione content of rat vs. rabbit conceptuses in vitro. Reprod Toxicol 13 (1999) 547-554
3. Schardein J.L. Thalidomide: the prototype teratogen. Chemically induced birth defects. 3rd edition, revised and expanded (2000), Marcel Dekker Inc., New York p. 89-120
4. Teo S.K., Denny K.H., Stirling D.I., Thomas S.D., Morseth S., and Hoberman A.M. Effects of thalidomide on developmental, peri- and postnatal function in female New Zealand white rabbits and offspring. Toxicol Sci 81 (2004) 379-389
5. Kalter H. Thalidomide. Teratology in the twentieth century-congenital malformations in humans and how their environmental causes were established (2003), Elsevier Science, Amsterdam p. 167-175
6. Yoshida T. Introduction. In: Yoshida T., and Fujimoto K. (Eds). The TPRC handbook on the care and management of the laboratory cynomolgus monkey (2006), Springer Japan, Tokyo 1-3
7. Delahunt C.S., and Lassen L.J. Thalidomide syndrome in monkeys. Science 146 (1964) 1300-1305
8. Hendrickx A.G. The sensitive period and malformation syndrome produced by thalidomide in the crab-eating monkey (Macaca fascicularis). J Med Prim 2 (1973) 267-276
9. Finnell R.H., Gelineau-van Waes J., Eudy J.D., and Rosenquist T.H. Molecular basis of environmentally induced birth defects. Ann Rev Pharmacol Toxicol 42 (2002) 181-208
10. Singh A.V., Knudsen K.B., and Knudsen T.B. Computational systems analysis of developmental toxicity: design, development and implementation of a birth defects systems manager (BDSM). Reprod Toxicol 19 (2005) 421-439
11. Daston G.P. Genomics and developmental risk assessment. Birth Defects Res (Part A) 79 (2007) 1-7
12. Green M.L., Singh A.V., Zhang Y., Nemeth K.A., Sulik K.K., and Knudsen T.B. Reprogramming of genetic networks during initiation of the fetal alcohol syndrome. Dev Dyn 236 (2007) 613-631
13. Knudsen T.B., and Kavlock R.J. Comparative bioinformatics and computational toxicology. In: Abbott B., and Hansen D. (Eds). Developmental toxicology. Target organ toxicology series vol. 3 (2008), Taylor and Francis, New York 311-360
14. ® Array Service http://www.genelogic.com/docs/pdfs/NHP_W.pdf [accessed September 14.09.07].
15. Institute of Laboratory Animal Research, Commission of Life Sciences, and National Research Council. Guide for the care and use of laboratory animals (1996), The National Academies Press, Washington, DC
16. Otey C.A., Rachlin A., Moza M., Arneman D., and Carpen O. The palladin/myotilin/myopalladin family of actin-associated scaffolds. Int Rev Cytol 246 (2005) 31-58
17. Yayoshi-Yamamoto S., Taniuchi I., and Watanabe T. FRL, a novel formin-related protein, binds to Rac and regulates cell motility and survival of macrophages. Mol Cell Biol 20 (2000) 6872-6881
18. Marignani P.A., and Carpenter C.L. Vav2 is required for cell spreading. J Cell Biol 154 (2001) 177-186
19. Brugneara E., Haney J., Grimsley C., Lu M., Walk S.F., Tosello-Trampont A.C., et al. Unconventional Rac-GEF activity is mediated through the Dock180-ELMO complex. Nat Cell Biol 4 (2002) 574-582
20. Katoh H., and Negishi M. RhoG activates Rac1 by direct interaction with the Dock180-binding protein Elmo. Nature 424 (2003) 461-464
21. Rosenberger G., Jantke I., Gal A., and Kutsche K. Interaction of alphaPIX (ARHGEF6) with beta-parvin (PARVB) suggests an involvement of alphaPIX in integrin-mediated signaling. Hum Mol Genet 12 (2003) 155-167
22. Shin E.Y., Woo K.N., Lee C.S., Koo S.H., Kim Y.G., Kim W.J., et al. Basic fibroblast growth factor stimulates activation of Rac1 through a p85 PIX phosphorylation-dependent pathway. J Biol Chem 279 (2004) 1994-2004
23. Burgering B.M., and Coffer P.J. Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature 376 (1995) 599-602
24. Franke T.F., Yang S.I., Chan T.O., Datta K., Kazlauskas A., Morrison D.K., et al. The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell 81 (1995) 727-736
25. Kohn A.D., Kovacina K.S., and Roth R.A. Insulin stimulates the kinase activity of RAC-PK, a pleckstrin homology domain containing ser/thr kinase. EMBO J 14 (1995) 4288-4295
26. Cross D.A., Alessi D.R., Cohen P., Andjelkovich M., and Hemmings B.A. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378 (1995) 785-789
27. Streck R.D., Wood T.L., Hsu M.S., and Pintar J.E. Insulin-like growth factor I and II and insulin-like growth factor binding protein-2 RNAs are expressed in adjacent tissues within rat embryonic and fetal limbs. Dev Biol 151 (1992) 586-596
28. van Kleffens M., Groffen C., Rosato R.R., van den Eijnde S.M., van Neck J.W., Lindenbergh-Kortleve D.J., et al. mRNA expression patterns of the IGF system during mouse limb bud development, determined by whole mount in situ hybridization. Mol Cell Endocrinol 138 (1998) 151-161
29. Stephens T.D., Bunde C.J., and Fillmore B.J. Mechanism of action in thalidomide teratogenesis. Biochem Pharmacol 59 (2000) 1489-1499
30. Dealy C.N., and Kosher R.A. Studies on insulin-like growth factor-I and insulin in chick limb morphogenesis. Dev Dyn 202 (1995) 67-79
31. Dealy C.N., and Kosher R.A. IGF-I, insulin and FGFs induce outgrowth of the limb buds of amelic mutant chick embryos. Development 122 (1996) 1323-1330
32. Mitchell P.J., Johnson S.E., and Hannon K. Insulin-like growth factor I stimulates myoblast expansion and myofiber development in the limb. Dev Dyn 223 (2002) 12-23
33. Knobloch J., Shaughnessy Jr. J.D., and Rüther U. Thalidomide induces limb deformities by perturbing the Bmp/Dkk1/Wnt signaling pathway. FASEB J 21 (2007) 1410-1421
34. Eisen T., Boshoff C., Mak I., Sapunar F., Vaughan M.M., Pyle L., et al. Continuous low dose thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer 82 (2000) 812-817
35. Ball S.G., Shuttleworth C.A., and Kielty C.M. Vascular endothelial growth factor can signal through platelet-derived growth factor receptors. J Cell Biol 177 (2007) 489-490
36. D'Amato R.J., Loughnan M.S., Flynn E., and Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91 (1994) 4082-4085
37. Seifert R., Zhao B., and Christ B. Cytokinetic studies on the aortic endothelium and limb bud vascularization in avian embryos. Anat Embryol (Berl) 186 (1992) 601-610
38. Therapontos C., Erskine L., Gardner E.R., Figg W.D., and Vargesson N. Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation. PNAS Early Edition (2009). http://www.pnas.org/cgi/doi/10.1073/pnas.0901505106
39. Hansen J.M., Harris K.K., Philbert M.A., and Harris C. Thalidomide modulates nuclear redox status and preferentially depletes glutathione in rabbit limb versus rat limb. J Pharmacol Exp Ther 300 (2002) 768-776